These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1949939)

  • 1. Human monoclonal antibody against endotoxin.
    Zarowitz BJ
    DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
    Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
    J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
    Luce JM
    Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
    Linden PK; Angus DC; Chelluri L; Branch RA
    J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to endotoxin in the treatment of gram-negative sepsis.
    McCabe WR
    JAMA; 1992 May; 267(17):2325; author reply 2326. PubMed ID: 1564763
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody to endotoxin in the treatment of gram-negative sepsis.
    van Deventer S
    JAMA; 1992 May; 267(17):2325-6. PubMed ID: 1564765
    [No Abstract]   [Full Text] [Related]  

  • 17. Human monoclonal antibodies in sepsis.
    de Koning J; Westendorp RG
    Neth J Med; 1992 Apr; 40(3-4):215. PubMed ID: 1603215
    [No Abstract]   [Full Text] [Related]  

  • 18. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
    Schulman KA; Glick HA; Rubin H; Eisenberg JM
    JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiendotoxin antibodies: a dead end?
    Cross AS
    Ann Intern Med; 1994 Jul; 121(1):58-60. PubMed ID: 8198349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.